Though an upregulation of TRPV1 has been reported by several authors in different PD models, both agonists and antagonists targeting these have been successful in alleviating symptoms of disease in the preclinical stages (Figure 1) (Nam et al., 2015; Li et al., 2019). This evidence concerns the gene TRPV1 and Parkinson disease.